ArticleCureus2025
Solitary Bone Plasmacytoma of the Scapula: A Rare Localization With Remarkable Radiotherapy Outcome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary bone plasmacytoma (SBP) is a rare plasma cell neoplasm characterized by localized proliferation of monoclonal plasma cells in bone without systemic involvement, which distinguishes it from multiple myeloma. Although the axial skeleton is most frequently affected, involvement of the shoulder girdle is exceptionally uncommon. We present the case of a 48-year-old woman who experienced progressive left shoulder pain and noted an enlarging mass over six months. Imaging revealed a large osteolytic lesion in the scapula with extension into surrounding soft tissue. Histopathology and immunohistochemistry confirmed the diagnosis of solitary plasmacytoma. Comprehensive staging, including bone marrow biopsy and 18F-FDG PET/CT (Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography), excluded systemic disease. The patient underwent definitive radiotherapy, receiving 50 Gy (Grays) in 25 fractions via a 3D (three-dimensional) conformal technique with careful target delineation. Treatment was well tolerated, with only grade I radiodermatitis reported. Follow-up imaging two months after therapy demonstrated significant lesion regression, partial re-ossification, and reduction of soft-tissue involvement. SBP of the scapula represents a rare clinical entity, and radiotherapy continues to be the treatment of choice, offering excellent local control. Despite favorable local outcomes, long-term monitoring is crucial due to the potential risk of progression to multiple myeloma. Documenting rare localizations contributes to a better understanding of disease behavior and supports tailored management approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.